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ABSTRACT
Background: A neonatal haemoglobinopathy screening
programme was implemented in Brussels more than a
decade ago and in Lie`ge 5 years ago; the programme
was adapted to the local situation.
Methods: Neonatal screening for haemoglobinopathies
was universal, performed using liquid cord blood
and an isoelectric focusing technique. All samples with
abnormalities underwent confirmatory testing. Major and
minor haemoglobinopathies were reported. Affected
children were referred to a specialist centre. A central
database in which all screening results were stored was
available and accessible to local care workers.
A central clinical database to monitor follow-up is under
construction.
Results: A total of 191 783 newborns were screened.
One hundred and twenty-three (1:1559) newborns were
diagnosed with sickle cell disease, seven (1:27 398) with
b thalassaemia major, five (1:38 357) with
haemoglobin H disease, and seven (1:27 398) with
haemoglobin C disease. All major haemoglobinopathies
were confirmed, and follow-up of the infants was
undertaken except for three infants who did not attend
the first medical consultation despite all efforts.
Conclusions: The universal neonatal screening pro-
gramme was effective because no case of major
haemoglobinopathy was identified after the neonatal
period. The affected children received dedicated medical
care from birth. The screening programme, and specifi-
cally the reporting of minor haemoglobinopathies, has
been an excellent health education tool in Belgium for
more than 12 years.
Migration has brought haemoglobinopathies to
north Europe and, within the European Union,
Belgium is one of the countries that is most
involved. Belgium now has around 10 million
inhabitants and an annual growth rate of around
0.54%. In 2005, the percentage of migrants coming
from countries with a high prevalence of haemo-
globinopathy was 3.9% of the total Belgian
population. To this number, one should add an
average number of 20 000 immigrants or children
born to immigrant parents per year (0.2% of the
total population per year) who acquired Belgian
nationality during the last decade.1 There are no
official data on the prevalence of haemoglobino-
pathies and no annual registration of new cases,
but an estimation of the prevalence and demo-
graphic picture of the major haemoglobinopathies
in Belgium has been recently approached through a
confidential inquiry.2 From a response rate of 42%
from all the Belgian adult internal medicine and
paediatric departments, 417 patients have been
reported, including 83% with sickle cell disease
(SCD), 13% with b thalassaemia major, 2% with
b thalassaemia intermedia, and 1% with
haemoglobin H disease.2
In 1994 the immigration context was known,
but neither the Belgian Authorities nor health
practitioners were aware of the incidence of
haemoglobinopathies and thus of the services that
needed to be implemented to reduce the burden of
those disorders. To follow English and French
programmes,3–6 it was decided to determine the
birth incidence of haemoglobinopathies in Brussels
at the end of 1994. That epidemiological approach
was soon transformed into the implementation of
a neonatal screening programme in Brussels and,
from 2002, also in Lie`ge. The Belgian Authorities
have not yet approved its extension to the entire
country.
The aim of the present article is to report our
experience with neonatal haemoglobinopathy
screening of more than 150 000 newborns and
the birth incidence of haemoglobinopathies in
Brussels and Lie`ge, and to try to outline the
screening approaches that have been chosen and




A universal neonatal screening for haemoglobino-
pathies has been in operation since December 1994
and September 2002 in Brussels and Lie`ge, respec-
tively. Becoming part of a national programme
‘‘Convention INAMI relative au de´pistage ne´onatal
des he´moglobinopathies en Re´gion de Bruxelles-
capitale’’ in 2003, the screening included all the
neonates born under the care of the Brussels
maternity services from that year. However it
included only one maternity service in Lie`ge
(Hoˆpital de la Citadelle). The programme was
quite separate from other mandatory testing at
birth, such as screening for phenylketonuria or
hypothyroidism. For each test, around J4.5 were
given to the reference centre and J0.5 to the
maternity service. The programme included all the
procedures as well as the integration of the results
into a central database.
Since 2006, a specific label entitled
‘‘Haemoglobinopathies screening’’ has been
attached to the baby’s medical record to certify
that the screening had been performed.
Patient data
Ethnicity and birth weight of the neonates as well
as a transfusion prior to the test were recorded.
The screening was approved by each local ethical
committee.
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Sample type and laboratory technique
Liquid cord blood samples in EDTA were analysed by an
isoelectric focusing (IEF) technique on agar gels, as previously
described (PerkinElmer Life Sciences, Zaventem, Belgium).7
Confirmation of results
All samples with suspected abnormal haemoglobin fractions on
IEF were further analysed by high-performance liquid chroma-
tography (HPLC) using the b-thalassaemia short programme kit
on a BioRad Variant (BioRad, Hercules, California, USA), as
previously described.7
A repeat sample was requested, before the family left the
maternity service, for newborns in whom no haemoglobin
(Hb)A or a very low level of HbA was detected, who had high
levels of Hb Bart’s or in whom there was a higher percentage of
a variant Hb than HbA.
Reporting results
In each maternity service, a local official neonatal screening
specialist was chosen. He or she was in charge of the local
implementation of the screening programme as well as of its
follow-up.
Major and minor haemoglobinopathies were reported.
Moreover, a central database in which all results were stored
was readily accessible to local healthcare workers.
Major haemoglobinopathies (eg, SCD) were reported without
delay by phone and by mail to those specialists who were
responsible for obtaining a repeat sample.
Minor haemoglobinopathies (eg, sickle cell trait) were
reported by regular mail within 2 weeks.
Follow-up
Tracking newborns that might have been missed by the
programme was implemented in two ways. If the specific label
entitled ‘‘Haemoglobinopathies screening’’ was not found in the
newborn record, a liquid heel prick sample at day 3 post-
delivery was used for screening. Moreover, with the database, it
was easy for each local neonatal screening specialist to identify
newborns who had been missed and who needed to be recalled
for testing.
Before leaving the maternity service, the families of an
affected newborn received counselling and were referred to a
specialised healthcare centre where an initial consultation was
scheduled. The reference centre ensured monitoring of affected
children. To do this, a form to be completed by the recipient,
incorporating questions regarding prenatal monitoring for the
couple, whether antenatal diagnosis had been offered and the
possible reason for its refusal as well as the name of the
paediatrician who would take care of the child, was sent to the
local official responsible for screening. From the beginning of the
screening, a centralised database that includes all the results of
screening has been accessible to local official neonatal screening
specialists. Since 2007, a centralised patient registry has allowed
the monitoring of outcome of affected children. Diagnosis,
significant events and treatment are retrospectively registered.
An annual follow-up is recorded.
Concerning the minor haemoglobinopathies, counselling the
families and the identification of previously unknown at-risk
couples was done in specialised healthcare centres wherever
there was a significant prevalence of haemoglobinopathies.
RESULTS
Patients
During the study period, 191 783 newborns were screened in
Brussels and Lie`ge. This represented annually around 13.5% of
all births in Belgium. Geographical origins of the neonates
screened in 2007 showed that 45% of the neonates had both
parents not of an ancestry at risk for a haemoglobinopathy
(table 1). The screening test revealed mainly two minor and one
major haemoglobinopathies (ie, 2929 (1:65) newborns were
found to have a sickle cell trait, 385 HbC trait, and 123 SCD)
(table 2). The most frequent haemoglobin variant encountered
in populations not at risk for a haemoglobinopathy was HbD-
Punjab. Out of 80 reported cases, 20 newborns were identified
on their name and the self-reported ethnicity of both their
parents of north European ancestry.
The other presumptive positive newborns for a major
haemoglobinopathy were seven newborns with b thalassaemia
major, five with HbH disease, and five with HbC disease. Of the
142 newborns found at screening to have a major haemoglo-
binopathy, all were retested and the presumptive diagnosis was
confirmed. As infants were still within the maternity service, it
was unnecessary to recall the families.
No newborns were misdiagnosed. No infant was reported to
have missed screening at birth and subsequently found to be
positive for a major haemoglobinopathy.
The origin registered for parents of SCD infants was sub-
Saharan Africa in 117 cases, North Africa in two cases, and a
mixed origin in four cases (Mediterranean basin and sub-
Saharan Africa or North Africa in three and one cases,
respectively). For infants with b thalassaemia major, the
parents’ origin was North Africa in four cases, the Middle
East in two cases, and a mixed origin in one case (Middle East
and Mediterranean basin). All parents originated from Asia in
cases of HbH disease.
Follow-up
After leaving the maternity hospital, and despite our efforts,
three families did not attend the first medical visit to a
specialised reference care centre.
Despite follow-up, death of two SCD newborns was
reported: one died of septicaemia when antibiotic prophylaxis
had been interrupted by the family, and one died from
respiratory distress not related to SCD.
All infants with b thalassaemia major or HbH disease are
alive. From the follow-up data in the retrospective centralised
database, serious complications and treatment will be known
for the screened newborns and comparison can be made with
those who did not benefit from screening.
Table 1 Geographical origin of the neonates screened in
Brussels maternity service in 2007








*At least one parent of ancestry at risk for a haemoglobinopathy.
{Excluding North Africa.
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Genetic counselling and prenatal diagnosis in the SCD newborns
families
For 88 newborns with a major haemoglobinopathy, information
regarding antenatal screening, genetic counselling and discus-
sion of prenatal diagnosis with the parents was recorded. This
represented 84 couples (two couples had twins, and two had
two SDC infants): six newborns had b thalassaemia major, and
78 had SCD. The first antenatal visit was later than the first
trimester in 22 cases (26%). No screening of the mother was
done in 20 cases (24%) of which three presented during the third
trimester and two had been screened during an earlier
pregnancy. Of the 65 mothers screened, 19 partners were not
available or refused to be tested. The genetic counselling was
carried out by a specialist in 28 cases. Prenatal diagnosis was
accepted in 21 cases. In two cases, an obstetrician misinter-
preted tests results and genetic counselling was not offered (two
cases of sickle cell/b thalassaemia compound heterozygosity).
DISCUSSION
In the European Union, four countries have adopted a neonatal
screening programme financed by the authorities in public
health: England, France, Belgium and recently The
Netherlands.3–7
It is interesting to know that estimated European prevalence
of conceptions with sickle cell disorders was the highest (ie,
higher than 0.20 per 1000) in England and Wales, The
Netherlands, Belgium, France, Portugal, Greece, Albania and
Cyprus.1
The screening policy adopted in Belgium varies in some
aspects compared with that of the other European countries.
First, the financed neonatal screening is not national but largely
limited to the capital city. It took 8 years to obtain funding by
the national health authorities, and it was restricted to Brussels.
Ongoing discussions with health authorities are focused on the
feasibility of antenatal screening, rather than on expanding
national neonatal screening. Such a project, not linked to
neonatal screening, was implemented in Portugal.8 As for
neonatal screening, a reference laboratory carried out the
haemoglobinopathy screening tests (quantification of HbA2
and HbF; detection and quantification of Hb variants) while the
red blood cell parameters were measured in a peripheral
laboratory. Thus it could serve as a model.
A different policy (ie, linkage of newborn screening with an
antenatal screening programme) has been adopted in England.
In fact there are two strategies: one for high prevalence areas
where all women are offered screening. and one for low
prevalence areas where a more complex algorithm has been
developed that is related to the red blood cell indices results and
the ethnic origin of the woman or her partner.3 4 This could be
an alternative model to restrictive policies offering only
antenatal screening (ie, Portugal) or only neonatal screening
(ie, France and The Netherlands).
Dried blood spots on filter paper from a heel prick have been
the specimen of choice for neonatal screening except in Belgium
where liquid cord blood is used. Heel prick on filter paper cards
is the standard specimen collection used in a reference
laboratory for screening for congenital hypothyroidism and
phenylketonuria.3–5 Naturally in most countries when the
neonatal screening was extended to haemoglobinopathies the
same specimen type was used. Liquid cord blood has been
chosen in Belgium since it has been implemented in a reference
laboratory for haemoglobinopathies and not in a reference
laboratory for screening for congenital hypothyroidism and
phenylketonuria. Moreover, the primary study had an epide-
miological purpose. It was very important that samples for
neonatal screening should not be confused with those of the
study. This gave us the opportunity to evaluate that type of
specimen collection. Liquid cord blood was very stable and
provided a high amount of sample for confirmation techniques
or DNA tests. When an affected newborn was identified, there
was another advantage: an immediate repeat sample could be
obtained in order to give the result of the screening to the
parents before discharge of the baby.
IEF and HPLC are the main screening techniques used. New
methods applicable to screening are now available (ie, capillary
electrophoresis, tandem mass spectrometry) or are under
development (ie, immunoassay).9–11 A capillary electrophoresis
system (Sebia Benelux, Brussels, Belgium) is under evaluation
and we will soon evaluate an immunoassay (Perkin Elmer,
Zaventem, Belgium).
In European countries, apart from the ethics, equity and
discrimination issues that may arise if universal screening is not
applied, it has been demonstrated that universal screening
identifies more newborns with disease and prevents more
deaths.12 The choice of the screening method is based on cost-
effectiveness and it has been demonstrated that at a prevalence
of at least 16 sickle cell trait/1000 and 0.5 SCD/1000 there is no
significant cost difference between universal and targeted
screening programmes.12 In Brussels and Lie`ge, these numbers
are applicable and universal screening was therefore chosen.
A neonatal haemoglobinopathy screening programme is an
opportunity to provide information to healthcare practitioners
and families, and withholding information from parents does
not seem justified. Nevertheless, others have highlighted the
potential risk of neonatal identification of carriers such as
inadvertent exposure of non-paternity, social stigma for the
individual and family, and adverse psychological effects for the
individual and family.13 In our experience, these aspects can be
taken into account and it was decided to report all the results.
However, the delivery of these results must be done by
specifically trained healthcare staff.
Follow-up of all the affected newborns should remain a major
goal of neonatal screening. To ensure monitoring of outcome, a
centralised patient registry was implemented in 2007. All SCD
patients living in Belgium will be included. The aims of this
database will be to evaluate the natural history of the disease









SS 92 (1:1954) 7 (1:1714)
SC 15 (1:11 986) 2 (1:5998)
Sb Thalassaemia 6 (1:29 965) 1 (1:11 995)
b Thalassaemia major 7 (1:25 684) –
H 5 (1:35 958) –
CC 7 (1:25 684) –
Trait
AS 2745 (1:65) 184 (1:65)
AC 354 (1:508) 31 (1:387)
AD-Punjab 80 (1:2247) 5 (1:2399)
AE 80 (1:2247) 12 (1:1000)
AO-Arab 40 (1:4495) –
Other variants 214 (1:840) 7 (1:1714)
Total newborns screened 179 788 11 995
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and to characterise our population in terms of demography,
medical history, family history and physical and laboratory
findings. Since neonatal screening has not been extended to the
whole country, it will be interesting to compare the outcomes
of SCD patients diagnosed at birth and those diagnosed later.
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